Olverembatinib combined with blinatumomab in treating T315I-mutated Philadelphia chromosome –positive acute lymphoblastic leukemia: two-case report

AbstractABL tyrosine kinase inhibitors (TKIs) act an irreplaceable role in the management of Philadelphia chromosome –positive (Ph+) acute lymphoblastic leukemia (ALL). The treatment of these diseases has been revolutionized by the application of immunotherapeutic modalities. However, diseases with ABL kinase domain mutation T315I are resistant to the majority of TKIs, which is responsible for treatment failure. Olverembatinib is a third-generation TKI that has been approved for the treatment of T315I-mutated chronic myeloid leukemia (CML) in China; its usage in Ph+ ALL needs further exploration. Here, we present two cases with relapsed T315I mutation Ph+ ALL who received the combination regimen of blinatu momab and olverembatinib. This regimen, which has not been reported yet, was safe and effective as the patients achieved minimal residual disease (MRD) negative after 1 cycle of therapy. The management of these cases provides evidence of this new chemo-free regimen as an efficient approach for relap sed or refractory(R/R)Ph+ ALL.
Source: Annals of Hematology - Category: Hematology Source Type: research